Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | COACH trial update: GemOx vs. GCb in cisplatin-unfit advanced urothelial carcinoma

Cisplatin-based chemotherapy is the standard treatment for advanced urothelial carcinoma (UC). However, up to half of patients are ineligible for cisplatin for various reasons. Jae-Lyun Lee, MD, of the Asan Medical Center, Seoul, South Korea, discusses the results from the Phase II COACH study, which investigated the efficacy and safety of gemcitabine-oxaliplatin (GemOx) compared with gemcitabine-carboplatin (GCb) in cisplatin-unfit advanced UC patients (NCT01487915). Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Lee reports that the toxicity profile of GemOx proved more tolerable than that of GCb, highlighting the potential of GemOx as a new treatment option for advanced UC.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.